Computerized Gaming Rehabilitation Program 1
DeviceBrain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
NCT Number: NCT03737825
WHO: 40 participants with a confirmed diagnosis of Multiple Sclerosis (MS) able to engage in moderate physical activity.
WHY: The purpose of this study is to evaluate two computerized brain training tools, which include light physical activity, to see if they can help improve cognitive functions, such as memory and attention, for patients with MS.
WHAT: Complete a set of tests (physical and cognitive) at baseline, wear a Fitbit Flex device at home for the duration of the study, 3 supervised sessions for 4 weeks at UCSF, one visit for physical and cognitive tests at one week after the final supervised session, and one final visit 6 months after the final supervised session.
WHERE: 20 participants at the UCSF Weill Institute for Neurosciences (675 Nelson Rising Lane, San Francisco, CA); 20 participants at Lausanne University Hospital (Rue du Bugnon 46, 1005 Lausanne, Switzerland)
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Lausanne University Hospital (CHUV), Lausanne, Switzerland
This is a dual-site trial with identical study activities taking place at both locations. If you live in/near San Francisco, study visits will take place at UCSF; if you live in/near Lausanne, Switzerland, study visits will take place at the Lausanne University Hospital.
You will be asked to attend one initial session for cognitive tests and answer questions regarding your medical history to see if you are eligible for the study. This process takes about 20 minutes. If you are eligible you will be asked to schedule the following appointments to participate:
First you will be randomized into one of two different training programs. You will not be able to choose which program you are placed in, but have equal chances of being randomized into each:
Baseline Visit: This session should take about two hours. You will be given some cognitive, visual and physical tests. You will be given questionnaires about your mood, fatigue and function. You will receive a Fitbit Flex to be worn daily for the duration of the study. The Fitbit will track daily active step count, number of active minutes, quality/length of sleep cycles.
Week 1-4 Visits (12 sessions in total): These sessions will be 1 hour and 30 minutes each (Note: the first session will be 2 hours to account for calibrations). You will come in three times a week for four weeks to attend on-site sessions. You will be asked to complete digital, cognitive and physical training at each one of these visits.
Post-Training Visit: You will be asked to come in for an assessment 1 week after completing your last training session. This visit will take about 2 hours. You will be asked to complete some cognitive, visual, and physical tests. You will be given questionnaires on mood, fatigue, and everyday function. You will also return the Fitbit you received at the start of the study.
A final follow-up visit will occur 6 months after you have completed your last training session. This visit will take about two hours. You will be asked to complete some cognitive, visual and physical tests. You will be given questionnaires on mood, fatigue and function.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
Time frame: 4 weeks
Processing speed is being measured by the Symbol Digit Modalities Test (SDMT) score. SDMT measures the time to pair abstract symbols with specific numbers. The test requires visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items in 90 seconds. (max=110, min=0). Higher scores indicate improvement. Lower scores indicate worsening.
Time frame: 4 weeks
Attention is measured by the Test of Variables of Attention (TOVA). This computerized culture- and language-free test uses both visual and auditory stimuli to assess the speed and accuracy of attentional processing deficits in the domain of attention (Greenberg, 1998). Initially devised for ADHD in children, its predictive power has been demonstrated in other patient groups with attention and memory impairments (Braverman et al., 2006): domains also largely impaired in MS. The TOVA has furthermore been chosen here because positive effects following BBT training in young adults have been observed on this test (ongoing study at the Neuroscape Center at UCSF, unpublished data).
Time frame: 4 weeks
Visual working memory will be assessed via performance on 'Filter task', an established assessment of visual working memory Vogel, McCollough, & Machizawa, 2005).
Time frame: 4 weeks
The Triangle Tracer module of ACE evaluates multitasking abilities and is based on the same principles as Neuroracer, UCSF Neuroscape's paradigm for assessment and training of multitasking (Anguera et al., 2013)
Time frame: 4 weeks
The Brief Visuospatial Memory Test (BVMT) is an immediate non-verbal recall test, and a standardized assessment tool of working memory in MS.
Time frame: 4 weeks
Mood is measured by the Center for Epidemiological Studies - Depression (CES-D), which asks participants to rank 20 different symptoms on a severity scale of 0 to 3. The score is the sum of these subscales (max=60, min=0). Scores of 16 or greater are indicative of higher risk for clinical depression.
Time frame: 4 weeks
Fatigue is being measured by the Modified Fatigue Impact Scale (MFIS) which has participants rank 21 items on 0 to 4 (never to always) scale. The score is the sum of these subscales. (max=84, min=0) Lower scores indicate improvement. Higher scores indicate worsening.
Time frame: 4 weeks
These outcomes will include MSQOL54 that has patients rank responses to 12 sub-scales: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. This provides a composite score (min=0, max=100) which can be broken down into two summary scores for physical health and mental health. These scores are derived from a weighted combination of scale scores.
Time frame: 4 weeks
The outcomes will include MSNQ composite score (min=0, max=60). Scores >27 indicate cognitive impairment.
Time frame: 4 weeks
The Rating Scale of Attentional Behavior (RSAB) is a 14-item questionnaire and validated standard assessment of everyday life attention. A higher composite score (min=0, max=75) indicates poor attentional behavior.
Time frame: 4 weeks
Both state and trait anxiety are measured by the State Trait Anxiety Inventory (STAI). The outcome is a composite score (min=20, max=80) for STAI-state and STAI-trait sub-scales. Higher scores indicate greater anxiety levels.
University of California, San Francisco
Other
Computerized Cognitive Training for Patients With Cognitive Deficits Due to Multiple Sclerosis: a Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06281314
Alzheimer Disease, Autoimmune Diseases
Messina, Sicily, Italy
View Trial DetailsNCT03569618
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
San Francisco, California, United States
View Trial DetailsNCT04806568
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Thessaloniki, Central Macedonia, Greece
View Trial DetailsNCT02290587
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bordeaux, France
View Trial Details